

Heidar Sharafi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2001660/publications.pdf>

Version: 2024-02-01

91
papers

969
citations

430843

18
h-index

552766

26
g-index

93
all docs

93
docs citations

93
times ranked

1230
citing authors

#	ARTICLE	IF	CITATIONS
1	An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study. <i>International Journal of Drug Policy</i> , 2022, 102, 103580.	3.3	5
2	Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study. <i>BMJ Open</i> , 2022, 12, e058757.	1.9	1
3	Association of single nucleotide polymorphisms in immune-related genes with spontaneous HBsAg seroconversion: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2022, 110, 108982.	3.8	1
4	Comment on "No evidence of occult HBV infection in population born after mass vaccination". <i>Wiener Medizinische Wochenschrift</i> , 2021, 171, 36-37.	1.1	0
5	Association of GSTM1 and GSTT1 Null Deletions and GSTP1 rs1695 Polymorphism with the Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. <i>Hepatitis Monthly</i> , 2021, 20, .	0.2	1
6	Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis. <i>Harm Reduction Journal</i> , 2021, 18, 12.	3.2	9
7	The Efficacy and Safety of Sofosbuvir/Daclatasvir Fixed-Dose Combination in Iranian Hemodialysis Patients with Hepatitis C Virus Infection. <i>Nephro-Urology Monthly</i> , 2021, 13, .	0.1	0
8	Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 29.	2.2	2
9	COVID-19 Among Patients With Hepatitis B or Hepatitis C: A Systematic Review. <i>Hepatitis Monthly</i> , 2021, 20, .	0.2	2
10	Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders. <i>Virology Journal</i> , 2021, 18, 199.	3.4	4
11	First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients. <i>BMC Gastroenterology</i> , 2021, 21, 443.	2.0	3
12	Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019. <i>Pathogens</i> , 2021, 10, 1522.	2.8	3
13	Changes in the distribution of etiologies of cirrhosis among patients referred for liver transplantation over 11 years in Iran. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 844-850.	1.6	5
14	Harm reduction during the COVID-19 outbreak in Iran. <i>Lancet Psychiatry</i> , 2020, 7, e57.	7.4	3
15	Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era. <i>Harm Reduction Journal</i> , 2020, 17, 80.	3.2	19
16	Systematic Review and Meta-Analysis of Global Prevalence of HBsAg and HIV and HCV Antibodies among People Who Inject Drugs and Female Sex Workers. <i>Pathogens</i> , 2020, 9, 432.	2.8	25
17	Global prevalence of HCV and/or HBV coinfections among people who inject drugs and female sex workers who live with HIV/AIDS: a systematic review and meta-analysis. <i>Archives of Virology</i> , 2020, 165, 1947-1958.	2.1	24
18	Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection. <i>Frontiers in Microbiology</i> , 2020, 11, 617375.	3.5	3

#	ARTICLE	IF	CITATIONS
19	Global Distribution of Hepatitis D Virus Genotypes: A Systematic Review. <i>Hepatitis Monthly</i> , 2020, 20, .	0.2	1
20	Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study. <i>Caspian Journal of Internal Medicine</i> , 2020, 11, 41-46.	0.2	1
21	Drug use and risk behaviour profile, and the prevalence of HIV, hepatitis C and hepatitis B among people with methamphetamine use in Iran. <i>International Journal of Drug Policy</i> , 2019, 73, 129-134.	3.3	18
22	Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank. <i>Microbial Drug Resistance</i> , 2019, 25, 1072-1079.	2.0	2
23	Performance of a rapid diagnostic test for screening of hepatitis C in a real-life prison setting. <i>Journal of Clinical Virology</i> , 2019, 113, 20-23.	3.1	21
24	The Rising Threat of Hepatocellular Carcinoma in the Middle East and North Africa Region: Results From Global Burden of Disease Study 2017. <i>Clinical Liver Disease</i> , 2019, 14, 219-223.	2.1	19
25	Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 577-610.	2.3	22
26	Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. <i>Virus Research</i> , 2019, 259, 54-61.	2.2	5
27	Aflatoxin B ₁ exposure and the risk of hepatocellular carcinoma in Iranian carriers of viral hepatitis B and C. <i>Toxin Reviews</i> , 2019, 38, 234-239.	3.4	8
28	Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or -3 Infections: A Systematic Review and Meta-Analysis. <i>Archives of Clinical Infectious Diseases</i> , 2019, In Press, .	0.2	1
29	Prevalence of Hepatitis B, Hepatitis C, and HIV Infections in Working Children of Afghan Immigrants in Two Supporting Centers in Tehran and Alborz Provinces, Iran. <i>Archives of Pediatric Infectious Diseases</i> , 2019, In Press, .	0.3	4
30	A facile PCR-RFLP method for genotyping of <i>ITPA</i> rs1127354 and rs7270101 polymorphisms. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, e22440.	2.1	3
31	Association of <i>PNPLA3</i> rs738409 polymorphism with liver steatosis but not with cirrhosis in patients with HBV infection: Systematic review with meta-analysis. <i>Journal of Gene Medicine</i> , 2018, 20, e3001.	2.8	4
32	Comment on "Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study". <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 807-808.	1.6	0
33	Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?. <i>World Journal of Hepatology</i> , 2018, 10, 543-548.	2.0	15
34	Hepatitis B and Hepatitis C in Patients with Inherited Disorders of Hemoglobin in Sistan and Baluchistan Province, Iran. <i>Archives of Clinical Infectious Diseases</i> , 2018, In Press, .	0.2	0
35	Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review. <i>Hepatitis Monthly</i> , 2018, In Press, .	0.2	1
36	A Simple PCR-RFLP Method for Genotyping of <i>IFNL4</i> rs368234815 Polymorphism in Patients With Chronic Hepatitis C. <i>Laboratory Medicine</i> , 2017, 48, 51-56.	1.2	7

#	ARTICLE	IF	CITATIONS
37	Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2017, 25, 11.	2.0	26
38	Impact of IFNL4rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon- α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C. <i>Journal of Clinical Laboratory Analysis</i> , 2017, 31, e22063.	2.1	15
39	The high diagnostic characteristics of HBsAg level in differentiation of hepatitis B clinical presentations: Myth or truth?. <i>Liver International</i> , 2017, 37, 620-621.	3.9	1
40	Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis. <i>Annals of Hepatology</i> , 2017, 16, 188-197.	1.5	19
41	Perspectives on NASH Histology: Cellular Ballooning. <i>Annals of Hepatology</i> , 2017, 16, 182-184.	1.5	43
42	Efficacy and Safety of Generic Sofosbuvir/Ledipasvir Fixed-Dose Combination in Iranian Patients with Chronic Hepatitis C Virus Infection. <i>Hepatitis Monthly</i> , 2017, 17, .	0.2	13
43	Treatment of Hepatitis C Infection with Direct-Acting Antiviral Agents in Liver-Transplant Patients: A Systematic Review and Meta-Analysis. <i>Hepatitis Monthly</i> , 2017, 17, .	0.2	3
44	Public Awareness Campaign and Knowledge of Iranian (Bio)Medical Students Regarding Hepatitis B and C Infections. <i>Hepatitis Monthly</i> , 2017, 17, .	0.2	7
45	The Role of Polymorphisms Near IFNL3 Gene as Predictors of Residual HCV RNA in Buffy Coat after Successful Antiviral Therapy. <i>Hepatitis Monthly</i> , 2017, 17, .	0.2	3
46	Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017. <i>Hepatitis Monthly</i> , 2017, 17, .	0.2	9
47	Assessment of Hepatitis C Virus RNA in Peripheral Blood Mononuclear Cells as a Predictor of Response to Pegylated-Interferon and Ribavirin: A Cohort Study. <i>Iranian Red Crescent Medical Journal</i> , 2017, 19, .	0.5	2
48	Seroprevalence of Hepatitis C Virus among Blood Donors in Middle Eastern Countries: A Systematic Review and Meta-Analysis. <i>Iranian Red Crescent Medical Journal</i> , 2017, 19, .	0.5	2
49	Comparison of MicroRNAs Between Hepatocytes and Peripheral Blood Mononuclear Cells Involved in Hepatitis C Virus Infection. <i>Thrita</i> , 2017, In Press, .	0.2	0
50	Polymorphisms of IFNL3 and Response to Interferon-Based Treatments in Patients with Hepatitis D Infection: Systematic Review and Meta-Analysis. <i>Iranian Red Crescent Medical Journal</i> , 2017, 19, .	0.5	0
51	The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis. <i>Hepatitis Monthly</i> , 2016, 16, e40357.	0.2	48
52	Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. <i>Hepatitis Monthly</i> , 2016, 16, e40959.	0.2	63
53	The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. <i>Journal of Research in Medical Sciences</i> , 2016, 21, 72.	0.9	11
54	Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, Iran. <i>Hepatitis Monthly</i> , 2016, 16, e32215.	0.2	28

#	ARTICLE	IF	CITATIONS
55	The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassaemic Patients With Hepatitis C. <i>Hepatitis Monthly</i> , 2016, 16, e32703.	0.2	22
56	The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C. <i>Hepatitis Monthly</i> , 2016, 16, e35278.	0.2	4
57	The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C. <i>Hepatitis Monthly</i> , 2016, 16, e37011.	0.2	9
58	Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. <i>Hepatitis Monthly</i> , 2016, 16, e37089.	0.2	66
59	Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review. <i>Hepatitis Monthly</i> , 2016, 16, e42938.	0.2	10
60	Tehran Hepatitis Conference: An International Meeting with the Goal of Middle East without Viral Hepatitis. <i>Hepatitis Monthly</i> , 2016, 16, .	0.2	0
61	The High Frequency of the C282Y-Mutant HFE Gene in Northeast Iran; New Finding or Genotyping Error?. <i>Iranian Red Crescent Medical Journal</i> , 2016, 18, .	0.5	0
62	Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 114-119.	1.8	10
63	Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients. <i>Jundishapur Journal of Microbiology</i> , 2015, 8, e21444.	0.5	11
64	High Response Rate to Pegylated Interferon Alpha and Ribavirin Combination Therapy in Hemophilic Children with Chronic Hepatitis C; A Case-Control Study. <i>Pediatric Hematology and Oncology</i> , 2015, 32, 399-405.	0.8	4
65	Prevalence and trends of transfusion-transmitted infections among blood donors in Tehran, Iran from 2008 to 2013. <i>Transfusion and Apheresis Science</i> , 2015, 53, 38-47.	1.0	15
66	The effect of polymorphisms of gamma-glutamyl hydrolase (GGH) gene on methotrexate-induced toxicity in acute lymphoblastic leukemia. <i>Toxin Reviews</i> , 2015, 34, 136-141.	3.4	2
67	Alanine transaminase as a single marker is not reliable for selecting candidates of pegylated interferon and ribavirin treatment. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 195-196.	1.7	0
68	Interferon- γ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. <i>World Journal of Gastroenterology</i> , 2015, 21, 8935.	3.3	26
69	Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassaemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy. <i>Hepatitis Monthly</i> , 2015, 15, e23564.	0.2	15
70	Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1. <i>Hepatitis Monthly</i> , 2015, 15, e24955.	0.2	6
71	Appropriate Genotyping of Hepatitis B Virus in Iran. <i>Jundishapur Journal of Microbiology</i> , 2015, 8, e23529.	0.5	1
72	How Can We Make Decision for Patients With Chronic Hepatitis B According to Hepatitis B Virus (HBV) DNA Level?. <i>Hepatitis Monthly</i> , 2014, 14, e15285.	0.2	8

#	ARTICLE	IF	CITATIONS
73	The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. <i>Hepatitis Monthly</i> , 2014, 14, e22649.	0.2	23
74	Differentiation of hepatitis B/hepatitis D coinfection and superinfection in asymptomatic blood donors: is it possible?. <i>Apmis</i> , 2014, 122, 1042-1042.	2.0	1
75	Can we include genetic variants with high linkage disequilibrium into a multiple logistic model?. <i>Liver International</i> , 2014, 34, 964-964.	3.9	4
76	How Can the IL28B Polymorphisms with Linkage Disequilibrium Affect the Natural Course of Hepatitis B Inversely?. <i>Liver International</i> , 2014, 34, 1127-1127.	3.9	0
77	Seroepidemiology and clinical features of hepatitis delta among HBsAg carriers: a study from Hepatitis Clinic of Iranian Blood Transfusion Organization. <i>Transfusion Medicine</i> , 2014, 24, 411-417.	1.1	12
78	Comment on "No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance" by Ubaldo Visco-Comandini et al. [<i>Dig. Liver Dis.</i> 2014;46:348-352]. <i>Digestive and Liver Disease</i> , 2014, 46, 761-762.	0.9	2
79	Seroepidemiology of human T-cell lymphotropic virus among Iranian adult thalassemic patients. <i>Transfusion Medicine</i> , 2014, 24, 227-232.	1.1	8
80	Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 343-343.	3.7	11
81	Association of -24CT, 1249CA, and 3972CT ABCC2 Gene Polymorphisms with Methotrexate Serum Levels and Toxic Side Effects in Children with Acute Lymphoblastic Leukemia. <i>Pediatric Hematology and Oncology</i> , 2014, 31, 169-177.	0.8	23
82	Interferon Alpha-2b Therapy in Chronic Hepatitis Delta. <i>Hepatitis Monthly</i> , 2014, 14, e15729.	0.2	5
83	Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis. <i>Hepatitis Monthly</i> , 2014, 14, e15895.	0.2	10
84	Interferon-Î» Genetic Variations and Hepatitis C: Yet to be Discovered. <i>Hepatitis Monthly</i> , 2014, 14, e19433.	0.2	3
85	What is the ethnicity-specific impact of genetic polymorphisms on the response to hepatitis C treatment in an admixed population of Brazilian patients?. <i>Clinics</i> , 2014, 69, 152.	1.5	0
86	Distribution of Human Papillomavirus Genotypes in Liquid-based Samples; Abundance of HPV-53 in Tehran, Iran. <i>Iranian Journal of Public Health</i> , 2014, 43, 1159-60.	0.5	8
87	IL28B Polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients. <i>Hepatitis Monthly</i> , 2012, 11, 958-959.	0.2	15
88	Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. <i>Hepatitis Monthly</i> , 2012, 12, e8387.	0.2	32
89	Development and Validation of a Simple, Rapid and Inexpensive PCRRFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. <i>Hepatitis Monthly</i> , 2012, 12, 190-195.	0.2	33
90	Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. <i>Hepatitis Monthly</i> , 2012, 12, 190-195.	0.2	24

#	ARTICLE	IF	CITATIONS
91	IL28B polymorphism,Explanation for Different Responses to Therapy in Hepatitis C Patients. Hepatitis Monthly, 2011, 11, 958-959.	0.2	9